CVS Health Corporation is considered one of the most undervalued low volatility stocks to buy now, with a Buy rating and $80 price target from Jefferies. UBS upgraded the stock to Buy with a $79 price target. In Q2 2025, CVS reported $98.9 billion in total revenues, an 8.4% increase from the previous year. The company’s GAAP diluted EPS was $0.80, with adjusted EPS at $1.81, and generated $6.5 billion in year-to-date cash flow from operations. The stock has a median price target of $71.93, indicating an 11.91% upside potential. CVS operates in healthcare benefits, health services, pharmacy & consumer wellness, and corporate/other segments. While CVS shows investment potential, other AI stocks may offer greater upside and less risk.

Read more at Yahoo Finance: Jefferies Reiterates a Buy Rating on CVS Health (CVS) With a PT of $80